Former Chief Research and Development Officer · BIOCRYST PHARMACEUTICALS INC (BCRX)

Helen Thackray

FY2025 is the first fiscal year CompBrief holds for Helen Thackray as a named executive officer of BIOCRYST PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$4,339,624

Compensation figures as of the proxy filed April 23, 2026 (DEF 14A).

Helen Thackray compensation by year

BIOCRYST PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as BIOCRYST PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$425,999
Bonus$0
Stock awards$1,168,791
Option awards$1,255,458
Non-equity incentive$756,112
Pension and deferred compensation$0
All other$733,264
Total$4,339,624

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOCRYST PHARMACEUTICALS INC DEF 14A filed April 23, 2026, accession 0001628280-26-026822, and prior-year filings. Open the filing on EDGAR.

BIOCRYST PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Jon StonehouseFormer President and Chief Executive Officer$12,951,082
Charles GayerPresident and Chief Executive Officer; Former Chief Commercial Officer$9,627,868
Babar GhiasChief Financial Officer$6,748,152
Alane BarnesChief Legal Officer and Corporate Secretary$5,616,032
Helen Thackray · this pageFormer Chief Research and Development Officer$4,339,624
Anthony DoyleFormer Chief Financial Officer and Treasurer$2,141,135

The full BIOCRYST PHARMACEUTICALS compensation record

free company brief

This page is one person within BIOCRYST PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIOCRYST PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOCRYST PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy